メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
設備
プロジェクト
研究成果
データセット
受賞
活動
授業
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
今井 千速
教授, 博士（医学） 新潟大学 2005年12月
小児科学講座
h-index
3219
被引用数
22
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
1997 …
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(83)
授業
(12)
フィンガープリント
Chihaya Imaiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Chimeric Antigen Receptor T Cells (CAR-T)
100%
T Cells
77%
Acute Lymphoblastic Leukemia
60%
Chemotherapy
56%
Leukemia
55%
Natural Killer Cells
45%
Japan
42%
4-1BB
42%
Hematopoietic Stem Cell Transplantation
32%
Anti-CD19
29%
Cytotoxicity
27%
Genetic Modification
26%
Pediatric
25%
Childhood Acute Lymphoblastic Leukemia
24%
Complete Remission
24%
Anti-CD38
22%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
21%
Leukemic Cells
21%
Hypomorphic mutation
20%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
19%
Leukemia Patients
19%
T Cell Immunotherapy
18%
BCP-ALL
18%
CD38
17%
Induction Failure
17%
Older Adults
17%
Lymphoma Cells
17%
Ectodermal Dysplasia
17%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
17%
Chimeric Antigen Receptor T-cell Therapy
17%
Overall Survival
16%
X-linked
16%
Nuclear factor-B
16%
NKp44
16%
Synovial Sarcoma
16%
Pediatric Patients
16%
B-cell non-Hodgkin Lymphoma (B-NHL)
15%
Interleukin-15 (IL-15)
13%
Tyrosine Kinase Inhibitor
13%
Osteosarcoma
13%
Tumor
13%
Rituximab
12%
Remission Induction
12%
Successful Treatment
12%
High Risk
11%
T-cell ALL
11%
Clinical Outcomes
11%
Signaling Receptor
11%
Cytotoxic Effect
11%
Newly Diagnosed
11%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
72%
Chemotherapy
67%
Leukemia
63%
T Cell
50%
Pediatrics
46%
Neoplasm
35%
Chimeric Antigen Receptor
34%
Hematopoietic Stem Cell Transplantation
31%
Natural Killer Cell
30%
B Cell
25%
Precursor
25%
Receptor
24%
Overall Survival
20%
Disease
20%
Infection
19%
Nuclear Factor
19%
Cell Therapy
18%
Osteosarcoma
17%
Synovial Sarcoma
16%
Chimeric Antigen Receptor T-Cell Immunotherapy
16%
Alternative Complement Pathway C3 C5 Convertase
16%
Cancer Cell
14%
Chimeric Antigen Receptor T-Cell
14%
Tyrosine-Kinase Inhibitor
13%
Central Nervous System
13%
Cell Line
13%
Cytotoxicity
13%
Anticarcinogen
12%
Human Leukocyte Antigen
12%
Spontaneous Remission
11%
Leukocyte
11%
Immune Deficiency
11%
Hemophagocytic Syndrome
11%
Survival Rate
10%
Leukemia Cell
10%
Synovial Sarcoma Cell
9%
Adolescence
9%
Messenger RNA
9%
Gene Fusion
9%
Malignant Neoplasm
9%
Drug Megadose
9%
Cancer Therapy
8%
Clinical Trial
8%
Cancer Chemotherapy
8%
Family History
8%
Stem Cell Therapy
8%
Carcinoma Cell Line
8%
Choroid Plexus Carcinoma
8%
Tamsulosin
8%
Vascular Disease
8%
Immunology and Microbiology
T Cell
89%
Natural Killer Cell
54%
Chimeric Antigen Receptor
43%
Cytotoxicity
33%
CD19
30%
CD38
25%
DNA Modification
24%
Cancer Cell
22%
B Cell
22%
Immunotherapy
21%
Myeloid
19%
Immunology
16%
Complement Factor B
16%
CD3 Antigen
12%
Interleukin 15
12%
Rituximab
11%
Lymphoma Cell
11%
Cell Line
11%
Immunodeficiency
11%
Chimeric Antigen Receptor T-Cell
11%
Reverse Transcriptase
11%
Methylation
11%
Leukemia Cell
10%
Lineages
10%
Human Leukocyte Antigen
10%
Hematopoietic Cell
9%
CD34
9%
Immunocompetent Cell
9%
Hematopoietic Stem Cell Transplantation
9%
Chimeric Antigen Receptor T-Cell Therapy
9%
Cell Transplantation
8%
Multi-Omics
8%
Cord Blood Stem Cell Transplantation
8%
Glycoprotein
8%
Mycobacterium Bovis BCG
8%
Epstein-Barr Virus Latent Membrane Protein 1
8%
Induced Pluripotent Stem Cell
8%
Haplotype
8%
Killer-Cell Immunoglobulin-Like Receptor
8%
Asthma
8%
Mosaicism
8%
Hypohidrotic Ectodermal Dysplasia
8%
Copy Number Variation
8%
Body Fat Distribution
8%
Cytokine Induced Killer Cell
8%
Eosinophil Count
8%
Eosinophil
8%
Hypogammaglobulinemia
8%
Acute Graft Versus Host Disease
8%
Subcutaneous Fat
8%
